Login
$NKTR
$36.29 -$0.15 (0.41%) After hours

$NKTR 8-K/A SEC Filings

Filed On Filing
30 Aug 2019 8-K/A: Other Events

As previously disclosed, on July 23, 2019, Nektar received a General Advice letter (“Letter”) from the U.S. Food and Drug Administration (“FDA”) regarding Nektar’s New Drug Application (“NDA”) for NKTR-181, a novel mu-opioid analgesic dr...

15 Jan 2016 8-K/A: Regulation FD Disclosure

On December 15, 2015, Messrs. Robin and Nicholson, Dr. Doberstein, Dr. Gergel, and Mr. Labrucherie were granted stock options to purchase 112,500, 44,000, 17,500, 25,000 and 44,000 shares, respectively, of the Company’s common stock purs...

13 Dec 2006 8-K/A: Departure/Election of Directors or Officers; Compensation

The following disclosures are made pursuant to paragraph (e) of Item 5.02.

16 Mar 2006 8-K/A: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

As discussed, this letter sets forth the substance of the transition and retirement agreement (the “Agreement”) that Nektar Therapeutics (the “Company”) is offering to you to aid in your employment transition.

08 Mar 2006 8-K/A: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

As discussed, this letter sets forth the substance of the transition agreement (the “Agreement”) that Nektar Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.

04 Oct 2001 8-K/A: Completion of Acquisition or Disposition of Assets

QuickLinks -- Click here to rapidly navigate through this document

04 Oct 2001 8-K/A: Completion of Acquisition or Disposition of Assets

QuickLinks -- Click here to rapidly navigate through this document

10 Aug 2001 8-K/A: Completion of Acquisition or Disposition of Assets

QuickLinks -- Click here to rapidly navigate through this document

20 Jun 2001 8-K/A: Other Events

San Carlos, Calif., June 20, 2001—Inhale Therapeutic Systems, Inc. (Nasdaq:INHL) today announced the English High Court of Justice ruled that Inhale's European patent covering room-temperature stable glassy materials is not valid in the ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support